Encode Ideas, L.P. Announces the Initiation of Research Coverage on Ocuphire Pharma Inc.

Dover, Delaware--(Newsfile Corp. - November 9, 2020) - Encode Ideas, L.P. Initiates Research on Ocuphire Pharma Inc. (NASDAQ: OCUP). The full research publication is available here^[1] and available on our website at www.encodelp.com^[2]. A summary follows:

Encode Ideas, L.P., a healthcare focused research firm, announced today it is initiating coverage on Ocuphire Pharma, Inc. (NASDAQ: OCUP). Ocuphire Pharma, Inc. is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size and improve visual acuity. Ocuphire's second product candidate, APX3330, is a twice-a-day oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema.

About us

Encode Ideas, L.P. is a healthcare focused research firm, founded in 2019, providing institutional quality research and actionable investment and trade ideas to the general investing public. We undertake an intensive research process to identify healthcare companies that are mispriced or underfollowed. This process lends us towards covering predominately micro / small cap securities, where we feel some of the most intriguing risk reward opportunities exist. Companies covered by Encode Ideas, L.P. will either fall under one or both of our Conviction Trade Ideas or Conviction Investment Idea series.

Disclosures

Full disclosures can be found at the end of the report, page 61, and on the website under the disclosure section. The securities of the issuer(s) discussed in this press release may be unsuitable for investors depending on their specific investment objectives and financial position.This research does not constitute a personal trading recommendation or take into account the particular investment objectives, financial situation or needs of an individual reader of this report and does not provide all of the pertinent information to make an investment decision. Neither Encode Ideas, L.P., nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. The information contained herein is based on sources that Encode Ideas, L.P. believes to be reliable but is not guaranteed to be accurate and does not purport to be a complete statement or summary of the available data. Encode Ideas, LP has been retained by Ocuphire Pharma, Inc. to provide investor awareness and research coverage. This compensation may constitute a conflict of interest as to Encode Ideas LP's ability to remain objective in our communication regarding the profiled company. Readers should always do their own due diligence and consult a financial professional.

Contact

Encode Ideas, L.P.email: ideas@encodelp.comtwitter: @encodelp^[3][4]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67755^[5]

References

1. ^{^} here (www.newsfilecorp.com)
2. ^{^} www.encodelp.com (www.newsfilecorp.com)
3. ^{^} ideas@encodelp.com (www.newsfilecorp.com)
4. ^{^} @encodelp (www.newsfilecorp.com)
5. ^{^} https://www.newsfilecorp.com/release/67755 (www.newsfilecorp.com)